PYX Resources: Achieving volume and diversification milestones. Watch the video here.
TP, even now I'm still optimistically hopeful for some profit even if not to the expectations heights of 2021 into early 2022. So, I'd be reluctant to jump too soon to accept break-even only to regret taking it a few months or a maybe a year later. I, for one, would not want BP to assume that shareholders are ready to accept pennies for their pounds. I may have to accept that in time ... but not yet.
Dare we report that our diverse range of pond-watchers seem to be collectively hinting from their various 'hides' that the hitherto random movement of our flock of various SNG-related Anas Platyrhynchos are starting to re-form again into something that may be reasonably considered to be reminiscent of a linear formation? .... or is that putting it too strong?
It's not hard to see from the profusion of IFN-related study reporting over the last 2+ years that we are already in the ballpark. Whilst figures of 11.8% relating to cohort presence of neutralising antibodies and 10% of COVID patients developing severe/critical manifestations may seem small, the associated worldwide figures of 770m infected (and that's just COVID) then we surely we must be on the bench at least, and just awaiting the call to join the game ... whilst remembering there are also other games in town looking for the same skill-set.
"With approximately 770 million confirmed infections and a tragic death toll nearing 7 million individuals worldwide, the virus continues to exert a profound impact. Although most individuals infected with SARS-CoV-2 exhibit minor symptoms, approximately 10% of patients develop severe or critical manifestations of the disease, often necessitating life-saving interventions such as mechanical ventilation."
... past well-informed and credible posters no longer share on here when any typo, slip-up or error is immediately pounced-upon and the author castigated. Glass houses comes to mind. Be the bigger person and cut some slack - you are sure to need it yourself in the hours , days and weeks ahead.
Interesting, but not surprising, that those able to reduce their avg are willing accept c. £1. Personally I'd be very disappointed, having felt unable to continue to invest and so retain a higher Feb '21 avg. Hopes for a return to its £2.50 highpoint may seem fanciful to many but it's where I'd hope to return if our ducks are all finally aligned with the stars .. and anything else that can be aligned.
Just my thoughts fwiw ...
We've been told what the nextstep is and the 6 month period (H1) in which it is intended to start (which is only 25 days in) ... I have no idea what the BoD are expected to say, not least that every word, syllable, tone or intonation would be microscopically examined leading to totally varied analyses. We would thereafter still be waiting for trial start notification. Whilst they did acknowledge PI's wish for more communication, it is obviously caveated by their oft repeated mantra of info only when there is info to impart .. or did I miss something. Never been a CEO so not qualified to comment on that perrenial issue.
.. or for the full year?
https://www.youtube.com/watch?v=ohDB5gbtaEQ
Surely after at least 3 years (if not more for some of us) everyone should be de-sensitised to slippage in the Pharma world generally and also radio silence specifically in terms of SNG's already admitted preference for news when there's actually something to say? It has been pretty clear for some time that H1 2024 was the next 'wake up' time, and we're still in 2023 expecting 'something'. The only thing that keeps me checking in is that there is clearly lots of research still going on and being reported - all of it continuing to appear very positive in terms of IFN and wider sector in general as well as the scientists claiming the continuing need for new and innovative solutions. Unless there is real bad news out there (that relates to SNG's planned P2's) that is somehow not being seen and shared either here or elsewhere, I fail to understand what appear to be disputes about nothing other than attempts to psycho-analyse anonymised fellow-shareholders ... or am I missing something? Thanks to those who are actually posting information - if there are any negative news/reports/publications etc negative I'm equally happy to hear of them and I can re-calibrate my otherwise positive (if delayed) hopes for SNG. GLA and enjoy some peace at Christmas.
From nothing other than 'gut reaction' I'm assuming (aren't we all) that the upcoming P2 'mini trials' are just that. A range of very small number (targeted) trials aiming at producing, asap, just sufficient data to (1) bolster/corroborate the original P2 results and (2) allow quick progression to a P3 with BP support. Given the winter targeting period I'm thinking data will be reasonably quickly received but the reporting process is the unknown quantity in terms of timescale and whether peer review is actually required. If BP (J&J) have early access to results then will this be enough for a P3 / JV to be on the table?
The riskiest thing on here is not the science or the product, it's the gamble to make definitive remarks and pontificate on competancy of those running the show without having all the information ( viz a viv) agreements, discussions and future plans that have been on-going not only with current collaborations but back to P2 results, if not before. The irony is still being here and allowing them to spend your money.
Thanks Spaceman ... nothing if not thought-provoking .. a tantalising 'what if' peek behind the veil?
Many posters on here (understandably) ask what on earth are all these high-profile (and high paid) post-holders doing all day. Assuming that having given detail of the mini P2's at the AGM they have indeed moved on to future strategising and the tactical planning that follows - well, what else could they be doing? I certainly would never even attempt to guess - it's not my world, but I do enjoy reading the what-ifs from others brave enough to share their thoughts - certainly better than just denouncing other views with no actual alternative to offer.